Among patients with relapsing multiple sclerosis, 450 mg of ublituximab could be safely infused in 30 minutes at week 24.

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.

The risk of developing MS and other demyelinating diseases is 3 times greater in individuals diagnosed with EBV-positive IM.

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.